ANI Pharmaceuticals (ANIP) Lowered to Hold at ValuEngine

ValuEngine cut shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a buy rating to a hold rating in a report released on Wednesday morning.

Several other analysts have also issued reports on ANIP. Canaccord Genuity set a $75.00 target price on ANI Pharmaceuticals and gave the stock a buy rating in a report on Saturday, December 9th. Zacks Investment Research raised ANI Pharmaceuticals from a hold rating to a buy rating and set a $71.00 target price on the stock in a report on Tuesday, November 7th. Finally, TheStreet raised ANI Pharmaceuticals from a c+ rating to a b rating in a report on Thursday, November 16th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $70.50.

ANI Pharmaceuticals (ANIP) traded down $0.20 during mid-day trading on Wednesday, reaching $63.38. The company’s stock had a trading volume of 162,918 shares, compared to its average volume of 182,823. The company has a quick ratio of 2.39, a current ratio of 3.45 and a debt-to-equity ratio of 0.83. The company has a market cap of $740.90, a PE ratio of 99.03 and a beta of 2.91. ANI Pharmaceuticals has a 1 year low of $42.23 and a 1 year high of $74.70.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.12. The firm had revenue of $48.16 million for the quarter, compared to analysts’ expectations of $48.12 million. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The company’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter last year, the business earned $1.09 EPS. equities research analysts expect that ANI Pharmaceuticals will post 3.59 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. Dimensional Fund Advisors LP boosted its stake in ANI Pharmaceuticals by 91.1% in the second quarter. Dimensional Fund Advisors LP now owns 339,268 shares of the specialty pharmaceutical company’s stock valued at $15,878,000 after buying an additional 161,743 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in ANI Pharmaceuticals by 868.2% in the third quarter. JPMorgan Chase & Co. now owns 104,829 shares of the specialty pharmaceutical company’s stock valued at $5,404,000 after buying an additional 94,002 shares in the last quarter. Vanguard Group Inc. boosted its stake in ANI Pharmaceuticals by 8.1% in the second quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock valued at $22,322,000 after buying an additional 35,722 shares in the last quarter. Cadence Capital Management LLC boosted its stake in ANI Pharmaceuticals by 422.2% in the third quarter. Cadence Capital Management LLC now owns 33,402 shares of the specialty pharmaceutical company’s stock valued at $1,753,000 after buying an additional 27,005 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ boosted its stake in ANI Pharmaceuticals by 85.5% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 54,900 shares of the specialty pharmaceutical company’s stock valued at $2,882,000 after buying an additional 25,300 shares in the last quarter. 55.05% of the stock is currently owned by institutional investors.

WARNING: “ANI Pharmaceuticals (ANIP) Lowered to Hold at ValuEngine” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.com-unik.info/2017/12/24/ani-pharmaceuticals-anip-lowered-to-hold-at-valuengine.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit